SCHEDULE: Vanguard Group Discloses 5.23% Passive Stake in aTyr Pharma

The Vanguard Group has reported a passive beneficial ownership of 5.23% in aTyr Pharma Inc., holding 4,655,048 shares of common stock.

Summary

• The Vanguard Group, an investment adviser, has filed a Schedule 13G indicating beneficial ownership of 4,655,048 shares of aTyr Pharma Inc. common stock.
• This ownership represents 5.23% of aTyr Pharma Inc.'s outstanding common stock.
• The filing date for this statement was July 29, 2025, based on an event date of June 30, 2025.
• The Vanguard Group holds sole dispositive power over 4,540,191 shares and shared dispositive power over 114,857 shares.
• The Vanguard Group holds sole voting power over 0 shares and shared voting power over 81,443 shares.
• The securities were acquired and are held in the ordinary course of business, without the purpose or effect of changing or influencing the control of aTyr Pharma Inc.

Sentiment

Score: 7

Explanation: The filing indicates a significant passive stake by a major institutional investor, The Vanguard Group, which can be viewed positively as it suggests inclusion in broad market indices or a vote of confidence, without implying any intent to influence company control.

Positives

• A major institutional investor, The Vanguard Group, has taken a significant passive stake (5.23%) in aTyr Pharma Inc., which may indicate inclusion in broad market indices or a vote of confidence in the company's long-term prospects.
• The passive nature of the investment, as certified by Vanguard, suggests stability and no immediate intent to influence corporate control.

Risks

• No specific risks related to aTyr Pharma Inc.'s operations or financial health are disclosed in this beneficial ownership filing, as it pertains solely to the reporting person's stake.

Future Outlook

No forward-looking statements or guidance regarding aTyr Pharma Inc.'s future operations or financial performance are provided in this beneficial ownership filing.

Management Comments

• The Vanguard Group certified that the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

This filing indicates a significant passive investment by a major institutional asset manager, The Vanguard Group, in aTyr Pharma Inc., a biotechnology company. Such investments are common for large index funds or diversified portfolios, reflecting aTyr Pharma's inclusion in relevant market indices or its general market capitalization.

Comparison to Industry Standards

• This beneficial ownership filing does not provide information for direct comparison to industry standards or specific comparable companies' results, as it focuses solely on the reporting entity's stake.

Stakeholder Impact

• Shareholders: Increased institutional ownership may provide stability and liquidity to the stock, potentially attracting further institutional interest.

Next Steps

• No specific future actions, events, or milestones for aTyr Pharma Inc. are mentioned in this beneficial ownership filing.

Key Dates

Recommendation

The filing indicates a significant passive stake by The Vanguard Group, a major institutional investor, in aTyr Pharma Inc. While this suggests the company is part of Vanguard's diversified portfolios or index funds, it does not provide specific operational or financial performance data to warrant a 'buy' or 'sell' recommendation. For existing shareholders, this institutional interest may offer some stability, hence a 'hold' is appropriate until further fundamental analysis is available.

Keywords

aTyr Pharma, Vanguard Group, Beneficial Ownership, Common Stock, Institutional Investor, Biotechnology, Pharmaceuticals, SEC Filing, Schedule 13G